Navigation Links
Sanofi Announces Court Ruling Granting Preliminary Injunction Against Synvisc-One® Competitor Product
Date:1/5/2012

BRIDGEWATER, N.J., Jan. 5, 2012 /PRNewswire/ -- Sanofi US today announced that the U. S. District Court in Massachusetts granted the company a preliminary injunction against a Synvisc-One® (hylan G-F 20) competitor product developed by Seikagaku Corporation. The ruling allows for a restricted launch of Seikagaku's product prior to a scheduled trial date in April, and prohibits Seikagaku from selling their product below the current average sales price for Synvisc-One.

(Logo:  http://photos.prnewswire.com/prnh/20110616/NY20158LOGO )

In its recent ruling, the Court found that Seikagaku was not likely to prevail at trial, which will focus on U.S. Patent 7,931,030.

"We are pleased that the Court recognized the strength of our '030 patent, which protects Genzyme's Synvisc-One® franchise," said Alison Lawton, Senior Vice President and General Manager of Sanofi's Biosurgery business. "We are also pleased that the Court took decisive steps to protect the market position that Genzyme earned through its research and development and product innovation."

Synvisc-One® has been the only single-injection viscosupplement for the treatment of osteoarthritis (OA) knee pain on the U.S. market since it was launched in the first quarter of 2009.  The market for such treatments is large, growing and underpenetrated; of the estimated 9 million eligible OA patients in the United States, only about 14 percent are currently treated with viscosupplements.

Sanofi's Biosurgery business, which markets a variety of products globally in the areas of osteoarthritis, postoperative adhesion prevention, and cell therapy, is focused on transforming disease management through innovative medical interventions.  It became part of Sanofi following the company's acquisition of Genzyme Corporation
'/>"/>

SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
3. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
8. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
9. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
10. Sanofi-aventis Stands Behind the Safety of Lantus(R)
11. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... 15, 2011 Echo Therapeutics, Inc. (OTC Bulletin Board: ... tCGM System as a non-invasive, wireless, transdermal continuous glucose ... transdermal drug delivery, today announced the appointment of William ... of Directors.  Echo,s Board now has a majority of ...
... 2011 Joyant Pharmaceuticals Inc. ("Joyant"), a privately-held pharmaceutical ... covering an entire class of anti-cancer therapeutics based upon ... targeting the apoptotic pathway and have broad potential for ... malignancies. The United States Patent and Trademark ...
Cached Medicine Technology:Echo Therapeutics Announces Appointments to Board of Directors 2Echo Therapeutics Announces Appointments to Board of Directors 3
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on conservation ... today examining the current state of knowledge of the ... improved global surveillance strategies to combat the emergence of ... in West Africa that has claimed the lives of ... According to the World Health Organization (WHO), the ...
(Date:4/17/2014)... Arias, M.D., Ph.D., at The University of Texas Health ... superbug that caused a bloodstream infection in a Brazilian ... of The New England Journal of Medicine . ... of highly-resistant bacteria known as methicillin-resistant Staphylococcus aureus ... hospital and community-associated infections. The superbug has also acquired ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... of the 1000 Genomes Project announced today that three ... have joined the international effort to build the most ... a tool for medical research. The new participants are: ... Biosystems, an Applera Corp. business, Foster City, Calif.; and ...
... Science,(Nasdaq: CSCX ), a global leader ... products, announced today,that it completed certification for ... Electronic Health Record (EHR)., (Logo: ... player in electronic health systems, with more,than ...
... children may have an impact on cardiovascular functioning equivalent ... to a research abstract that will be presented Wednesday ... Associated Professional Sleep Societies (APSS). , The study, authored ... Melbourne and Monash University, Melbourne, Victoria, Australia, focused on ...
... Ill. Widowed seniors are more likely to have disrupted ... event, according to a research abstract that will be presented ... the Associated Professional Sleep Societies (APSS). , The study, authored ... focused on 28 spousally bereaved seniors aged 60 years and ...
... insomnia delivered via the Internet can significantly improve insomnia ... be presented on Wednesday at SLEEP 2008, the 22nd ... , The study, authored by Lee Ritterband, PhD, of ... female) with an average age of 45 years. ...
... DaVita Inc., a leading,provider of kidney care ... disease (CKD), recently announced that Debbie Benner, MA, ... and Mary,Burgess, RD, Grant Program Manager for DaVita ... at the XIV International Congress on,Nutrition and Metabolism ...
Cached Medicine News:Health News:3 sequencing companies join 1000 Genomes Project 2Health News:3 sequencing companies join 1000 Genomes Project 3Health News:3 sequencing companies join 1000 Genomes Project 4Health News:3 sequencing companies join 1000 Genomes Project 5Health News:HeartCentrix Informatics Solution from Cardiac Science Now Certified with Allscripts Electronic Health Records 2Health News:HeartCentrix Informatics Solution from Cardiac Science Now Certified with Allscripts Electronic Health Records 3Health News:Primary snoring in children impacts cardiovascular functioning 2Health News:Primary snoring in children impacts cardiovascular functioning 3Health News:Disturbed sleep is prevalent in widowed seniors 2Health News:A self-help program delivered online can improve insomnia in adults 2Health News:DaVita Dietitians to Speak at the International Congress on Nutrition and Metabolism in Renal Disease in France 2
... MICROSTAAR injector contains a plunger style advance, ... be resterilized for multiple use. The injector ... accepts only STAAR cartridges. These injectors are ... This system was designed specifically ...
... the fundamental capsulotmy laser - the unique Ultra ... 2855% less energy in air at approximately 1.8 ... This technology eliminates the occurrence of hot ... pitting. , , , Ultra Q ...
... system is an innovative, robust and ... excellent clinical performance. The digital broadband ... the ES500 system deliver excellent tissue ... system offers a full suite of ...
Protects the eye during or after surgery or trauma. 8mm diameter, lint free keeps cornea moist. Protects retina from operating microscope light rays....
Medicine Products: